Study of VIB7734 for the Treatment of Moderate to Severely Active SLE

NCT04925934 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
214
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Amgen